Growth hormone treatment in children with idiopathic short stature: correlation of growth response with peripheral thyroid hormone action

Susperreguy, Sebastián; Muñoz, Liliana; Tkalenko, Natalia; Mascanfroni, Iván; Alamino, Vanina Alejandra; Montesinos, María M.; Masini-Repiso, Ana M.; Miras, Mirta; Pellizas, Claudia G.

doi:10.1111/j.1365-2265.2010.03924.x

Cited by 5 publications

(4 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The authors reported that the higher increase in TRα1 and TRα2 mRNAs levels after 12 months of GH treatment was positively correlated to the gain of growth velocity and bone markers. Moreover, they observed a better gain in growth velocity in response to GH therapy in the individuals who had the higher increase of TRα1 mRNA level [61]. This finding is in line with the main role of TRα1 in bone longitudinal growth and suggests a possible direct influence of GH on thyroid hormone receptors in the growth plate.…”

Section: Gh Impact On Thyroid Hormone Receptorssupporting

confidence: 59%

“…The presence of thyroid hormone receptors (TRs) in growth plates is well known [60]. Susperreguy et al [61] reported that the individual growth response in patients with idiopathic short stature treated with rhGH correlated positively with the change in the TRα mRNA level and negatively with the TRβ mRNA level. The design of the study was based on the evaluation of mRNA of TRs in peripheral blood mononuclear cells; however; there was a parallel evaluation of serum sex hormone binding globulin which, reflects the effect of thyroid hormones on the liver, and also osteocalcin and b-cross laps, which are serum biochemical markers reflecting thyroid hormone action at the bone tissue.…”

Section: Gh Impact On Thyroid Hormone Receptorsmentioning

confidence: 99%

See 1 more Smart Citation

Thyroid Hormone Changes Related to Growth Hormone Therapy in Growth Hormone Deficient Patients

Kucharská

Witkowska–Sędek

Rumińska

et al. 2021

JCM

View full text Add to dashboard Cite

The alterations in thyroid function during recombinant human growth hormone (rhGH) treatment have been reported by many authors since this therapy became widely available for patients with growth hormone deficiency (GHD). Decrease of thyroxine level is the most frequent observation in patients treated with rhGH. This paper presents literature data describing changes in thyroid function related to rhGH therapy and a current explanation of mechanisms involved in this phenomenon. The effect of GH on the hypothalamic-pituitary-thyroid (HPT) axis is dependent on a multilevel regulation beginning from influence on the central axis, thyroid, and extra-thyroidal deiodinases activity as well as the impact on thyroid hormone receptors on the end. Changes in central and peripheral regulation could overlap during rhGH therapy, resulting in central hypothyroidism or an isolated slight deficiency of thyroxine. The regular monitoring of thyroid function is recommended in patients treated with rhGH and the decision of levothyroxine (L-thyroxine) supplementation should be made in the clinical context, taking into account thyroid hormone levels, as well as the chance for satisfactory growth improvement.

show abstract

Section: Gh Impact On Thyroid Hormone Receptorssupporting

confidence: 59%

Section: Gh Impact On Thyroid Hormone Receptorsmentioning

confidence: 99%

Thyroid Hormone Changes Related to Growth Hormone Therapy in Growth Hormone Deficient Patients

Kucharská

Witkowska–Sędek

Rumińska

et al. 2021

JCM

View full text Add to dashboard Cite

show abstract

“…This FT4 decline was regarded as a reflection of mild central hypothyroidism. Even though the etiology of declining FT4 as result of mild central hypothyroidism and (mild) ESS may not be comparable, we hypothesize that prolonged lowered thyroid hormone concentrations in (non-acutely ill) children with cancer may contribute to adverse late effects, such as short stature, weight gain, dyslipidemia, fatigue or the pathogenesis of early frailty, on childhood cancer survivors [14,[21][22][23]. Therefore, we aim to follow thyroid hormone parameters in relation to these possible adverse late effects until the end of cancer treatment in this large prospective cohort.…”

Section: Discussionmentioning

confidence: 99%

Thyroid Profile in the First Three Months after Starting Treatment in Children with Newly Diagnosed Cancer

Lebbink

Bos

Dierselhuis

et al. 2023

Cancers

View full text Add to dashboard Cite

Background: Thyroid hormone anomalies during childhood might affect neurological development, school performance and quality of life, as well as daily energy, growth, body mass index and bone development. Thyroid dysfunction (hypo- or hyperthyroidism) may occur during childhood cancer treatment, although its prevalence is unknown. The thyroid profile may also change as a form of adaptation during illness, which is called euthyroid sick syndrome (ESS). In children with central hypothyroidism, a decline in FT4 of >20% has been shown to be clinically relevant. We aimed to quantify the percentage, severity and risk factors of a changing thyroid profile in the first three months of childhood cancer treatment. Methods: In 284 children with newly diagnosed cancer, a prospective evaluation of the thyroid profile was performed at diagnosis and three months after starting treatment. Results: Subclinical hypothyroidism was found in 8.2% and 2.9% of children and subclinical hyperthyroidism in 3.6% and in 0.7% of children at diagnosis and after three months, respectively. ESS was present in 1.5% of children after three months. In 28% of children, FT4 concentration decreased by ≥20%. Conclusions: Children with cancer are at low risk of developing hypo- or hyperthyroidism in the first three months after starting treatment but may develop a significant decline in FT4 concentrations. Future studies are needed to investigate the clinical consequences thereof.

show abstract

“…It is known that mild thyroid insufficiency may diminish tissue sensitivity to growth hormone in normal children [13]. The same occurs in children with DS.…”

mentioning

confidence: 95%

Subclinical hypothyroidism in children with Down syndrome: To treat or not to treat???

Elsayed

2014

Egyptian Journal of Medical Human Genetics

View full text Add to dashboard Cite

Growth hormone treatment in children with idiopathic short stature: correlation of growth response with peripheral thyroid hormone action

Abstract: GH therapy induced individual changes in TR expression in ISS that correlated with their growth response. The basal TR mRNA level could predetermine the change in TR expression and therefore the sensitivity to GH treatment.

Cited by 5 publications

References 37 publications

Thyroid Hormone Changes Related to Growth Hormone Therapy in Growth Hormone Deficient Patients

Thyroid Hormone Changes Related to Growth Hormone Therapy in Growth Hormone Deficient Patients

Thyroid Profile in the First Three Months after Starting Treatment in Children with Newly Diagnosed Cancer

Subclinical hypothyroidism in children with Down syndrome: To treat or not to treat???

Contact Info

Product

Resources

About